Vir Biotechnology (VIR) Non Operating Income (2018 - 2026)
Vir Biotechnology (VIR) posted Non Operating Income of $6.8 million for Q1 2026, up 39.17% sequentially from $4.9 million in Q4 2025, and down 63.63% YoY from $18.6 million in Q1 2025.
Vir Biotechnology (VIR) Non Operating Income (2018 - 2026) Analysis & Trends
Vir Biotechnology has reported Non Operating Income for 9 years, with the latest figure at $6.8 million in Q1 2026.
- Quarterly Non Operating Income fell 63.63% year-over-year to $6.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.7 million (down 56.01% YoY) and the FY2025 annual result came in at $41.6 million, down 35.13% from the prior year.
- Non Operating Income climbed to $6.8 million in Q1 2026 per VIR's latest filing, from $4.9 million in the prior quarter.
- Over five years, Non Operating Income peaked at $22.8 million in Q3 2022 and troughed at -$91.9 million in Q1 2022.
- A 5-year average of $5.3 million and a median of $12.5 million in 2024 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2022 and 2024: Non Operating Income tumbled 1101.06% in 2022, then soared 8140.98% in 2024.
- Over 5 years, Non Operating Income stood at -$1.1 million in 2022, then soared by 1707.31% to $18.3 million in 2023, then tumbled by 31.68% to $12.5 million in 2024, then slumped by 61.03% to $4.9 million in 2025, then jumped by 39.17% to $6.8 million in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $6.8 million, $4.9 million, and $10.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Vir Biotechnology | 1.56 Bn | 1.56 Bn | 238.95 Mn | 6.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.79 Mn |
| Mar 31, 2026 | 6.77 Mn |
| Dec 31, 2025 | 4.86 Mn |
| Sep 30, 2025 | 10.47 Mn |
| Jun 30, 2025 | 7.63 Mn |
| Mar 31, 2025 | 18.60 Mn |
| Dec 31, 2024 | 12.48 Mn |
| Sep 30, 2024 | 17.76 Mn |
| Jun 30, 2024 | 18.74 Mn |
| Mar 31, 2024 | 15.08 Mn |
| Dec 31, 2023 | 18.26 Mn |
| Sep 30, 2023 | 20.11 Mn |
| Jun 30, 2023 | 17.56 Mn |
| Mar 31, 2023 | 183,000.00 |
| Dec 31, 2022 | -1.14 Mn |
| Sep 30, 2022 | 22.77 Mn |
| Jun 30, 2022 | -8.50 Mn |
| Mar 31, 2022 | -91.92 Mn |
| Dec 31, 2021 | -25.86 Mn |
| Sep 30, 2021 | 164.15 Mn |